Biotechnology Value Fund II LP

Companies

K Kymera Therapeutics, Inc.Director, See Remarks and Footnotes −$174M

Open-market trades from SEC Form 4 only: no grants, option exercises or gifts. People are matched by the name on their filings, so two people with the same name share this page. For information only — not investment advice.